Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity ...

Accomplished RNA therapeutics leader with track record of advancing novel genetic medicines from discovery to FDA approval to ...

Adenosine deaminase acting on RNA (ADAR) is the enzyme responsible for adenosine-to-inosine (A-to-I) RNA editing, a process ...

Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and ...

Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...

Last week, biotechnology company Ascidian Therapeutics announced a manufacturing partnership with gene-therapy–focused ...

Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.

Learn more about whether Perrigo Company plc or Wave Life Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, ...

The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...

ProQR is developing RNA therapies based on its proprietary Axiomer RNA editing technology platform. The ongoing Phase 1 study of AX-0810, which targets NTCP for cholestatic diseases such as primary ...

A research team led by Associate Professor Hirofumi Nishizono and graduate student Masaki Kato from the Research Support ...